Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine for pain and respiratory outcomes after bariatric surgery
IRCT20221110056459N2Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bupivacaine in class III obesity (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Postoperative pain and Postoperative respiratory condition. Started Nov 2024; status: completed.
02
Drugs
bupivacaine
03
Conditions
class III obesity
Beyond the preview
Go deeper on IRCT20221110056459N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221110056459N2.